CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.91. Losses, adjusted for non-recurring costs, came to $2.50 per share.
The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of $2.69 per share.
The biotechnology company posted revenue of $966 million in the period, also beating Street forecasts. Nine analysts surveyed by Zacks expected $956.1 million.
Moderna expects full-year revenue in the range of $1.5 billion to $2.5 billion.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRNA at https://www.zacks.com/ap/MRNA
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。